Cargando…
Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis
AIMS: Changes of serum galectin-3 (Gal-3) is associated with the pathogenesis of diabetic nephropathy (DN). However, current literature indicates that the given results remain debatable and inconsistent. Hence, the aim of this present meta-analysis was to focus on the predictive role of serum Gal-3...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249253/ https://www.ncbi.nlm.nih.gov/pubmed/37291488 http://dx.doi.org/10.1186/s12882-023-03226-x |
_version_ | 1785055520849133568 |
---|---|
author | Guo, Yong Li, Ling Hu, Shanbiao |
author_facet | Guo, Yong Li, Ling Hu, Shanbiao |
author_sort | Guo, Yong |
collection | PubMed |
description | AIMS: Changes of serum galectin-3 (Gal-3) is associated with the pathogenesis of diabetic nephropathy (DN). However, current literature indicates that the given results remain debatable and inconsistent. Hence, the aim of this present meta-analysis was to focus on the predictive role of serum Gal-3 in patients with DN. METHODS: The PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched for studies that reported the relationship between Gal-3 levels and DN risk, from the inception of each database to March, 2023. The literature we selected for inclusion based on inclusion and exclusion criteria. The standard mean difference (SMD) with corresponding 95% confidence intervals (95% CI) were used to investigate the association. When I(2) value exceeding 50%, we will consider it has the presence of a higher level of heterogeneity. A sensitivity analysis and subgroup analysis were performed to seek the potential sources of heterogeneity. The quality assessment was performed using according to the Newcastle–Ottawa Quality Assessment Scale (NOS). The data analysis was conducted using STATA version 13.0 software. RESULTS: We ultimately enrolled 9 studies enrolling a total of 3137 patients in the final analysis. The SMD of serum Gal-3 was higher in patients with DN group (SMD 1.10 ng/mL [0.63, 1.57]; I(2): 96.1%). Upon removal of a study in sensitivity analysis, patients with DN had higher serum Gal-3 levels compared to control patients (SMD 1.03 ng/mL [0.52, 1.54], I(2): 94.4%). Further subgroup analysis was performed based on the region. No matter in Asia, Europe or Africa, the serum Gal-3 level of DN patients is significantly higher than that of the control population (SMD: 0.73; 95% CI: 0.58 to 0.87 for Asian; SMD: 0.79; 95% CI: 0.48 to 1.10 for Europe; SMD: 3.15; 95% CI: 2.73 to 3.56 for Africa). CONCLUSION: In conclusion, these results suggested that higher serum Gal-3 may increase the risk of DN. More fundamental studies are necessary to clarify the exact physiopathological basis mechanisms of Gal-3 effects. In addition, further research, especially emphasis on the cut-off value should be given, and is best to predict their actual importance as well as the diagnostic accuracy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03226-x. |
format | Online Article Text |
id | pubmed-10249253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102492532023-06-09 Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis Guo, Yong Li, Ling Hu, Shanbiao BMC Nephrol Research AIMS: Changes of serum galectin-3 (Gal-3) is associated with the pathogenesis of diabetic nephropathy (DN). However, current literature indicates that the given results remain debatable and inconsistent. Hence, the aim of this present meta-analysis was to focus on the predictive role of serum Gal-3 in patients with DN. METHODS: The PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched for studies that reported the relationship between Gal-3 levels and DN risk, from the inception of each database to March, 2023. The literature we selected for inclusion based on inclusion and exclusion criteria. The standard mean difference (SMD) with corresponding 95% confidence intervals (95% CI) were used to investigate the association. When I(2) value exceeding 50%, we will consider it has the presence of a higher level of heterogeneity. A sensitivity analysis and subgroup analysis were performed to seek the potential sources of heterogeneity. The quality assessment was performed using according to the Newcastle–Ottawa Quality Assessment Scale (NOS). The data analysis was conducted using STATA version 13.0 software. RESULTS: We ultimately enrolled 9 studies enrolling a total of 3137 patients in the final analysis. The SMD of serum Gal-3 was higher in patients with DN group (SMD 1.10 ng/mL [0.63, 1.57]; I(2): 96.1%). Upon removal of a study in sensitivity analysis, patients with DN had higher serum Gal-3 levels compared to control patients (SMD 1.03 ng/mL [0.52, 1.54], I(2): 94.4%). Further subgroup analysis was performed based on the region. No matter in Asia, Europe or Africa, the serum Gal-3 level of DN patients is significantly higher than that of the control population (SMD: 0.73; 95% CI: 0.58 to 0.87 for Asian; SMD: 0.79; 95% CI: 0.48 to 1.10 for Europe; SMD: 3.15; 95% CI: 2.73 to 3.56 for Africa). CONCLUSION: In conclusion, these results suggested that higher serum Gal-3 may increase the risk of DN. More fundamental studies are necessary to clarify the exact physiopathological basis mechanisms of Gal-3 effects. In addition, further research, especially emphasis on the cut-off value should be given, and is best to predict their actual importance as well as the diagnostic accuracy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03226-x. BioMed Central 2023-06-08 /pmc/articles/PMC10249253/ /pubmed/37291488 http://dx.doi.org/10.1186/s12882-023-03226-x Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Guo, Yong Li, Ling Hu, Shanbiao Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis |
title | Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis |
title_full | Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis |
title_fullStr | Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis |
title_full_unstemmed | Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis |
title_short | Circulating Galectin-3 levels and Diabetic Nephropathy: a systematic review and meta-analysis |
title_sort | circulating galectin-3 levels and diabetic nephropathy: a systematic review and meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249253/ https://www.ncbi.nlm.nih.gov/pubmed/37291488 http://dx.doi.org/10.1186/s12882-023-03226-x |
work_keys_str_mv | AT guoyong circulatinggalectin3levelsanddiabeticnephropathyasystematicreviewandmetaanalysis AT liling circulatinggalectin3levelsanddiabeticnephropathyasystematicreviewandmetaanalysis AT hushanbiao circulatinggalectin3levelsanddiabeticnephropathyasystematicreviewandmetaanalysis |